论文部分内容阅读
正在酝酿的国民经济和社会发展第十三个五年规划是以习近平主席为核心的新一届政府的首个五年计划,也正值我国经济进入创新驱动和转型升级发展的新常态时期。前不久国务院印发的《中国制造2025》中所列亟待突破性发展的10大重点领域,其中就有生物医药,有针对性的列举了重大疾病的生物技术药物新产品及其制剂等,重点包括新机制和新靶点抗体药物、抗体偶联药物、全新结构蛋白及多肽药物、新型疫苗、
The 13th Five-Year Plan for National Economic and Social Development under discussion is the first five-year plan of the new government with Xi Jinping as the core. It is also just when the Chinese economy has entered a new normal period of innovation-driven, transformation and upgrading. Not long ago, the State Council issued the “Made in China 2025” listed in the 10 key areas of urgent need for breakthrough development, including biomedicine, targeted a list of major diseases of new biotechnology drugs and their formulations, etc., focusing on New Mechanisms and New Targets Antibody Drugs, Antibody Coupling Drugs, New Structural Proteins and Peptide Drugs, Novel Vaccines,